HIPRA and Elanco Animal Health have partnered to bring two avian metapneumovirus (aMPV) vaccines to the U.S. poultry market, providing new tools for producers to manage this costly respiratory disease. The virus primarily affects turkeys, with an estimated 60-80% of commercial turkey flocks nationwide impacted by aMPV; yet broilers, and laying and breeding birds are also susceptible to the virus.

The vaccines, RESPIVAC® aMPV and HIPRAVIAR® TRT, manufactured by HIPRA, were introduced to select producers via an emergency import license earlier in 2025 through field trials. The field trials show significant improvement among vaccinated birds compared to the previous year.